Company Overview
MAIA Biotechnology, Inc. is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of telomerase-positive cancer cells.
Stock Information
Letter to Shareholders
Shareholder Letter (March 2024)Latest Presentation
Recent Event
Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
EMAIL ALERTS
Sign up today and receive company updates straight to your inbox.